final program.qxd - Parallels Plesk Panel

26) Kaiser S, Hass HG, Gregor M. Successful retreatment of interferon ribavirin non responders with daily dosing of consensus interferon
[abstract].. J Hepatol 2005; 42: 207-208.
27) Cornberg M, Hadem J , Herrmann E et al. Treatement with daily consensus interferon plus ribavirin in non responderrs patients
with chronic hepatitis C a randomized open label pilot study. J Hepatol 2006; 44: 291-301.
28) Leevy CB, Chalmers C, Blatt L. Comparison of African-American and non-African-American patients' end of treatment response for
PEG-IFN alpha 2a plus weight-based ribavirin non responders retreated with IFN Alfacon-1 plus weight-based ribavirin [abstract].
Hepatology 2004;40: 240A
29) Afdhal N, Flamm S, JC. I, PF. M, Tong M, Herrine S, et al. Analyses of 40 kDa peginterferon alfa-2a (PEGASYS®) in combination
with ribavirin, mycophenolate mofetil, amantadine, or amantadine plus ribavirin in patients that relapsed or did not respond to
RebetronTM therapy: A report of two randomized, multicenter, efficacy and safety studies. Hepatology 2001;34: 243A. Abstract 77.
30) Lodato F, Azzaroli F, Brillanti S, Colecchia A, Tame MR, Montagnani M, et al. Higher doses of peginterferon alpha-2b administered
twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized
study. J Viral Hepat 2005;12: 536-42.
31) Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a
(40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol 2005;17: 899-
904
32) Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type
1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130: 1086-97.
33) Sanchez Tapias JM, Diago M, Escartin P, et al. Sustained virological response after prolonged treatment with peginterferon alfa-2a
and ribavirin in treatment-naive patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: TERAVIC study
[abstract]. J Hepatol 2004;40: 150. Updater Gastroenterology 2006; in press.
34) Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic
hepatitis C and cirrhosis. N Engl J Med 2000;343: 1673-80.
35) Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis
C who have sustained response to interferon therapy. Ann Intern Med 2000;132: 517-24.
36) Lissen E, Clumeck N, Sola R, Correa M, Montaner J, Nelson M, et al. Histological response to peginterferon alfa-2a (40KD) (PEGA-
SYS®) plus ribavirin (COPEGUS®) in patients with HIV-HCV co-infection: results of the AIDS PEGASYS Ribavirin International Coinfection
Trial (APRICOT). Hepatology 2004;40 (Suppl 1): 241A. Abstract 174.
37) Curry M, Cardenas A, Afdhal NH. Effect of maintenance peg-intron therapy on portal hypertension and its complications: results
from the copilot study [abstract]. J Hepatol 2005;2005: Suppl. 2.
38) Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance
interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117: 1164-72.
39) Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial
of interferon nonresponders. Gastroenterology 2000;118: 655-60.
40) Ideo G, Bellobuono A, Tempini S, Mondazzi L, Airoldi A, Benetti G, et al. Antioxidant drugs combined with alpha-interferon in chronic
hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Eur J Gastroenterol Hepatol 1999;11: 1203-
7.
41) Takagi H, Kakizaki S, Sohara N, Sato K, Tsukioka G, Tago Y, et al. Pilot clinical trial of the use of alpha-tocopherol for the prevention
of hepatocellular carcinoma in patients with liver cirrhosis. Int J Vitam Nutr Res 2003;73: 411-5.
42) Rustgi V , Nelson D, Balan V, et al. A phase 2 escalation study of albuferon combined with ribavirin in non responders to prior interferon
based therapy for chornic hepatitis C infection ( abstract) . J Hepatol 2006; 44: S51.
43) McHutchison JG, Shiffman ML, Cheung RC, Gordon SC, Wright TL, Pottage JC, Jr., et al. A randomized, double-blind, placebocontrolled
dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
Antivir Ther 2005;10: 635-43.
44)
Afdhal N, Rodriguez-Torres M, Lawitz E, et al. Enhanced antiviral efficacy for valopicitabine plus Peg-interferon with hepatitis C patients
with HCV genotype 1 infection: results of a phase IIa multicenter trial [abstract]. J Hepatol 2005;42: 39-40.
45) Reesink HW, Forestiuer N , Weegink CJ, et al. Initial results of a 14 day study of the hepatitis C virus inhibitor protease VX950 in
combination with peginterferon alpha 2A (abstract). J Hepatol 2006; 44: S272.
46) Zeuzem S, Serrazin C, Wagner F, Rouzier R, Forestier N, Gupta S. The HCV NS3 protease inhibitor SCH503034 in combination
with Peg-IFNanon-responders: antiviral activity and HCV variant analysis. J Hepatol 2006;44. Abstract 78.
“ Focusing FIRST on PEOPLE “ 78 w w w . i s h e i d . c o m